What is the difference between Ogivri and Herceptin?
Medically reviewed by Drugs.com. Last updated on Sep 16, 2019.

Official Answer
by Drugs.comOgivri (trastuzumab-dkst) is a biosimilar to Herceptin (trastuzumab).
A biosimilar is a biological product that is FDA-approved and highly similar to a biologic already FDA-approved with no clinically meaningful differences in terms of safety and effectiveness from the reference product.
What Are Biosimilars? Top Facts You May Not Know
Ogivri and Herceptin are both used for the treatment of patients with HER2+ breast cancer or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).
Ogivri has not been approved as an interchangeable biosimilar, meaning the pharmacist cannot substitute Ogivri for Herceptin without consulting the prescriber. Note that pharmacy laws and practices vary from state to state.
For more information, see Comparing Ogivri vs Herceptin
Related Medical Questions
- What are the biosimilars of Herceptin?
- What is the difference between Herceptin and Herceptin Hylecta?
- What is the difference between Herzuma and Herceptin?
- How long can you stay on Herceptin and Perjeta?
- How many biosimilars have been approved in the United States?
- How long does Herceptin stay in your body?
- What is Herceptin? Is Herceptin a chemo drug? How does it work?
Drug Information
Related Support Groups
- Herceptin (12 questions, 26 members)
- Trastuzumab
- Ogivri
- Breast Cancer (83 questions, 266 members)
- Gastric Cancer (15 questions, 12 members)